During CAR-T cell treatment, a high accumulation of CAR-T cells occurs in the normal lung and abdominal/mediastinal lymph nodes, on which HER2 is expressed, although at a low level [27], which could reduce the efficiency of tumor treatment. This evidence concerns the gene ERBB2 and neoplasm.